A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs HQP 1351 (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 15 Oct 2019 Planned End Date changed from 15 Jul 2020 to 30 Oct 2020.
- 15 Oct 2019 Planned primary completion date changed from 15 Jul 2019 to 30 Oct 2020.
- 15 Oct 2019 Status has been changed to recruiting.